LY3437943

1. LY3437943 decreases body weight in humans (placebo-adjusted, dose-dependent) (up to -8.96 kg (90% CI -11.16 to -6.75) in the 3/6/9/12 mg group).

   “Placebo-adjusted bodyweight reduction with LY3437943 appeared to be dose dependent (up to -8·96 kg [90% CI -11·16 to -6·75] in the 3/6/9/12 mg group).”

   Human trialplacebo-adjusted, dose-dependentup to 3/6/9/12 mg once weekly12 weeksn = 72

   LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

   Lancet (London, England)·Oct 27, 2022

2. LY3437943 decreases body weight in obese mice.

   “In obese mice, administration of LY3437943 decreased body weight and improved glycemic control.”

   Animalsin obese mice

   LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

   Cell metabolism·Aug 18, 2022

1. LY3437943 decreases glycated hemoglobin A1c in humans (placebo-adjusted, week 12) (-1.4% (90% CI -2.17 to -0.56) for 3 mg; -1.6% for 3/6 mg).

   “Placebo-adjusted sHbA1c also decreased significantly in the three highest dose groups”

   Human trialplacebo-adjusted, week 123 mg, 3/6 mg and 3/6/9/12 mg once weekly12 weeksn = 72

   LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

   Lancet (London, England)·Oct 27, 2022

More on Glycated hemoglobin A1c

1. LY3437943 decreases plasma glucose in humans (placebo-adjusted, week 12) (-2.8 mmol/L (90% CI -4.63 to -0.94) for 3 mg; -3.1 mmol/L for 3/6 mg).

   “placebo-adjusted mean daily plasma glucose significantly decreased from baseline at the three highest dose LY3437943 groups”

   Human trialplacebo-adjusted, week 123 mg, 3/6 mg and 3/6/9/12 mg once weekly12 weeksn = 72

   LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

   Lancet (London, England)·Oct 27, 2022

More on Plasma glucose

1. LY3437943 increases energy expenditure in mice (GCGR-mediated activity).

   “Body weight loss was augmented by the addition of GCGR-mediated increases in energy expenditure”

   AnimalsGCGR-mediated activity

   LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

   Cell metabolism·Aug 18, 2022

1. LY3437943 is associated with gastrointestinal adverse events in humans (treatment-emergent adverse events) (63% of LY3437943 participants reported treatment-emergent adverse events; 54% placebo).

   “with gastrointestinal disorders being the most frequently reported treatment-emergent adverse events”

   Human trialtreatment-emergent adverse events12 weeksn = 72

   LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

   Lancet (London, England)·Oct 27, 2022